Logo image of NAMS

NEWAMSTERDAM PHARMA CO NV (NAMS) Stock News

NASDAQ:NAMS - Nasdaq - NL00150012L7 - Common Stock - Currency: USD

20.16  +0.02 (+0.1%)

After market: 20.16 0 (0%)

NAMS Latest News, Press Relases and Analysis

News Image
18 hours ago - Chartmill

Get insights into the top gainers and losers of Monday's pre-market session.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Mentions: BPT NCL PLCE SATS ...

News Image
14 hours ago - Benzinga

Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib

NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.

News Image
19 hours ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome...

News Image
5 days ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

News Image
14 days ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...

News Image
a month ago - Zacks Investment Research

Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 132.5% in NewAmsterdam Pharma Company N.V. (NAMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News Image
a month ago - Zacks Investment Research

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.89% and 7.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: MGX

News Image
a month ago - Zacks Investment Research

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 200% and 26.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: AKBA

News Image
a month ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at...

News Image
a month ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The...

News Image
a month ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...

News Image
a month ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers

News Image
a month ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein...

News Image
a month ago - Yahoo Finance

NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among […]

Mentions: DHI CMG TSLA

News Image
2 months ago - Yahoo Finance

Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic […]

Mentions: DHI CMG AAPL

News Image
2 months ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...

News Image
2 months ago - Yahoo Finance

NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V (NASDAQ:NAMS) stands against other Billionaire Stanley Druckenmiller’s other top stock picks with huge upside potential. Wall Street is overflowing with data. If […]

Mentions: FDX DAKT BRBR OXY ...

News Image
2 months ago - Yahoo Finance

Nissan sells its Indian plant to Renault to raise cash

Sale is part of broader restructuring of the Alliance.

Mentions: RIVN AMZN

News Image
2 months ago - Investor's Business Daily

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Mentions: AZN MRK REGN SNY ...

News Image
2 months ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...

News Image
3 months ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- ...

News Image
3 months ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...

News Image
4 months ago - NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...